Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 24.4% in January

Takeda Pharmaceutical Company Limited (NYSE:TAK) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 3,710,000 shares, a decline of 24.4% from the December 31st total of 4,910,000 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is presently 2.2 days.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TAK. Public Employees Retirement System of Ohio acquired a new position in Takeda Pharmaceutical in the third quarter valued at approximately $601,000. Verition Fund Management LLC bought a new position in Takeda Pharmaceutical during the 3rd quarter worth $1,533,000. HighTower Advisors LLC increased its position in Takeda Pharmaceutical by 199.5% in the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after buying an additional 81,653 shares during the period. XTX Topco Ltd bought a new stake in Takeda Pharmaceutical in the third quarter valued at $957,000. Finally, Creative Planning boosted its holdings in shares of Takeda Pharmaceutical by 46.3% during the third quarter. Creative Planning now owns 157,630 shares of the company’s stock valued at $2,242,000 after acquiring an additional 49,871 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $13.68 on Friday. Takeda Pharmaceutical has a 52-week low of $12.57 and a 52-week high of $15.08. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The firm has a market cap of $43.51 billion, a price-to-earnings ratio of 23.58, a PEG ratio of 0.24 and a beta of 0.51. The business’s 50 day moving average is $13.30 and its two-hundred day moving average is $13.89.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. Analysts forecast that Takeda Pharmaceutical will post 1.55 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.